Graphene based Nanomedicine therapy targeting Metastatic Tumor-Endothelial Interface | Department of Life Sciences

Graphene based Nanomedicine therapy targeting Metastatic Tumor-Endothelial Interface

Shivani Shirbhate, B.Sc.(Research) Biotechnology; Faculty Advisor – Dr. Seema Sehrawat, Department of Life Sciences, SoNS

Krüppel-like factor 4 (KLF4), a zinc finger-containing transcription factor, regulates diverse cellular processes, including apoptosis, metabolism, and cell cycle progression as well as stem cell renewal.

KLF4 acts as an oncogene or a tumor suppressor depending on the tissue context. In the primary breast ductal carcinoma, KLF4 acts as an oncogene and is highly expressed in the respective tumor cell population. It is highly expressed in 70% of the breast cancers however the mechanism by which it causes tumor formation and tumor progression is unknown.

Studies have reported that KLF4 plays an oncogenic role in breast cancer tumorigenesis by influencing cell migration, proliferation, cell invasion and maintaining stem cell like properties of the of a selective tumor cell population.

This makes KLF4 another strong target for anti-angiogenesis and anti-cancer drug development. The study of cumulative effect of silencing EPAC1 and KLF4 in breast cancer cells and observing the phenotypic effect on the cancer cell population has not been carried out yet.

The use of Graphene Oxide as a nano delivery vehicle increases the specificity of drug delivery directly to the cancer cells, thus not damaging the healthy cells. There have been very few reports of successful drug delivery by Graphene oxide using more than one drug molecule.


Associate Professor